Evaluation of clarithromycin on TNF-a serum level in patients with multiple sclerosis
Phase 2
Recruiting
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20100119003106N41
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Age of 20 t 60 years
Confirmed diagnosis of primary progressive progressive MS
No medical history of allergy to clarithromycin
Exclusion Criteria
Pregnancy or breast feeding patients
Serious underlying medical conditions (e.g malignancy, renal and hepatic failure)
Known hypersensitivity to clarithromycin and excipients
Significant signs of depression
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TNF-a. Timepoint: Before intervention and 2, 6, 8 weeks after intervention. Method of measurement: ELISA Kit.;Quality of life. Timepoint: before intervention and 2, 6, 8 weeks after intervention. Method of measurement: The quality of life questionnaire.
- Secondary Outcome Measures
Name Time Method